Referências
Principais artigos
Brooks BR, Miller RG, Swash M, et al; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299. Resumo
Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73:1227-1233.Texto completo Resumo
Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73:1218-1226. [Errata in: Neurology. 2009;73:2134; Neurology. 2010;74:781.]Texto completo Resumo
Artigos de referência
1. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647-653. Resumo
2. Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol. 2007;64:232-236.Texto completo Resumo
3. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554. Resumo
4. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4:771-780. Resumo
5. Beck M, Giess R, Magnus T, et al. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:68-70. Resumo
6. Shimizu T, Kawata A, Kato S, et al. Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology. 2000;54:1534-1537. Resumo
7. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3-9. Resumo
8. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68:1002-1007. Resumo
9. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589-602. Resumo
10. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. Resumo
11. Rockenstein E, Crews L, Masliah E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev. 2007;59:1093-1102. Resumo
12. Okado-Matsumoto A, Fridovich, I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc Natl Acad Sci U S A. 2002;99:9010-9014.Texto completo Resumo
13. Urushitani M, Kurisu J, Tsukita K, et al. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem. 2002;83:1030-1042. Resumo
14. Rakhit R, Cunningham P, Furtos-Matei A, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277:47551-47556.Texto completo Resumo
15. Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol. 2007;82:1-27. Resumo
16. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62. Resumo
17. Borchelt DR. Amyotrophic lateral sclerosis - are microglia killing motor neurons? N Engl J Med. 2006;355:1611-1613. Resumo
18. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495-505. Resumo
19. Lin H, Schlaepfer WW. Role of neurofilament aggregation in motor neuron disease. Ann Neurol. 2006;60:399-406. Resumo
20. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098.Texto completo Resumo
21. Benatar M, Kurent J, Moore DH. Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2009;(1):CD006153. Resumo
22. Lee CN. Reviewing evidences on the management of patients with motor neuron disease. Hong Kong Med J. 2012;18:48-55.Texto completo Resumo
23. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:62-73. Resumo
24. Rowland LP. Hereditary and acquired motor neuron diseases. In: Rowland LP, ed. Merritt's Neurology. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000:708-714.
25. Pablo J, Banack SA, Cox PA, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzeimer’s disease. Acata Neurol Scand. 2009;120:216-225. Resumo
26. Kuzuhara S. Revisit to Kii ALS - the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology. Brain Nerve. 2007;59:1065-1074. Resumo
27. Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology. 2005;64:32-37. Resumo
28. Veldink JH, Kalmijn S, Groeneveld GJ, et al. Physical activity and the association with sporadic ALS. Neurology. 2005;64:241-245. Resumo
29. Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005;128:472-476.Texto completo Resumo
30. Kamel F, Umbach DM, Munsat TL, et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology. 1999;18:194-202. Resumo
31. Nelson LM, McGuire V, Longstreth WT Jr, et al. Population-based case control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol. 2000;151:156-163.Texto completo Resumo
32. Alonso A, Logroscino G, Hernán MA. Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81:1249-1252. Resumo
33. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009;73:1693-1698.Texto completo Resumo
34. McGuire V, Longstreth WT Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol. 1997;145:1076-1088.Texto completo Resumo
35. Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002;13:311-319. Resumo
36. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary neurology series, volume 49. Philadelphia, PA: FA Davis; 1998:480.
37. Rowland LP, Muscular Dystrophy Association. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Advances in neurology, volume 56. New York, NY: Raven Press; 1991:569.
38. Brooks BR, Sanjak M, Belden D, et al. Natural history in amyotrophic lateral sclerosis - impairment, disability, handicap. In: Brown RH Jr., Meininger V, Swash M, eds. Amyotrophic lateral sclerosis. London: Dunitz; 2000:31-58.
39. Shoesmith CL, Findlater K, Rowe A, et al. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry. 2007;78:629-631. Resumo
40. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012;19:360-375. Resumo
41. Shipe C, Zivkovic SA. Electrodiagnostic evaluation of motor neuron disorders. Am J Electroneurodiagnostic Technol. 2004;44:30-36. Resumo
42. de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:344-352. Resumo
43. Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve. 2000;23:1488-1502. Resumo
44. Raaphorst J, de Visser M, Linssen WH, et al. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Lateral Scler. 2010;11:27-37. Resumo
45. Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17:337-341. Resumo
46. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077-1079. Resumo
47. Kornberg, AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve. 1994;17:100-104. Resumo
48. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73-78. Resumo
49. Gourie-Devi M, Nalini A. Long-term follow-up of 44 patients with brachial monomelic amyotrophy. Acta Neurol Scand. 2003;107:215-220. Resumo
50. Blexrud MD, Windebank AJ, Daube JR. Long-term follow-up of 121 patients with benign fasciculations. Ann Neurol. 1993;34:622-625. Resumo
51. Chasens ER, Umlauf MG. Post-polio syndrome. Am J Nurs. 2000;100:60-63;65;67. Resumo
52. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994 Jul;124 Suppl:96-107. Resumo
53. Brooks BR, Miller RG, Swash M, et al; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299. Resumo
54. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73:1227-1233.Texto completo Resumo
55. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65:1264-1267. Resumo
56. Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948-950. Resumo
57. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin. 2001;19:829-847. Resumo
58. National Institute for Health and Care Excellence. Motor neurone disease: assessment and management. Jul 2019 [internet publication].Texto completo
59. Munroe CA, Sirdofsky MD, Kuru T, et al. End-of-life decision making in 42 patients with amyotrophic lateral sclerosis. Respir Care. 2007;52:996-999.Texto completo Resumo
60. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.Texto completo Resumo
61. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73:1218-1226. [Errata in: Neurology. 2009;73:2134; Neurology. 2010;74:781.]Texto completo Resumo
62. Jia H, Xu YM. Evidence-based evaluation of therapeutic measures for amyotrophic lateral sclerosis [in Chinese]. Chin J Contemp Neurol Neurosurg. 2012;12:275-281.Texto completo
63. Weber G, Bitterman H. Riluzole-induced neutropenia. Neurology. 2004;62:1648. Resumo
64. Sanofi-Aventis. Rilutek® (riluzole) tablets: prescribing information. November 2012. http://products.sanofi.usTexto completo
65. Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005;171:269-274.Texto completo Resumo
66. Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017 Oct 6;10:CD004427.Texto completo Resumo
67. Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997;127:450-453. Resumo
68. Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology. 2006;67:761-765. Resumo
69. Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol. 2003;23:97-104. Resumo
70. McKim DA, Road J, Avendano M, et al; Canadian Thoracic Society Home Mechanical Ventilation Committee. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18:197-215.Texto completo Resumo
71. Moss AH, Casey P, Stocking CB, et al. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes. Neurology. 1993;43:438-443. Resumo
72. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;(10):CD007354.Texto completo Resumo
73. Katzberg, HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2011;(1):CD004030.Texto completo Resumo
74. Chio A, Finnochiaro E, Meineri P, et al; ALS Percutaneous Endoscopic Gastrostomy Study Group. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53:1123-1125. Resumo
75. ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015;14:702-709.Texto completo Resumo
76. Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage. 2009;37:246-258. Resumo
77. Tysnes OB. Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurol Scand Suppl. 2008;188:77-81. Resumo
78. McGeachan AJ, Mcdermott CJ. Management of oral secretions in neurological disease. Pract Neurol. 2017;17:96-103.Texto completo Resumo
79. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693-702. Resumo
80. Lui AJ, Byl NN. A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis. J Neurol Physical Therapy. 2009;33:68-87. Resumo
81. Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;(5):CD005229.Texto completo Resumo
82. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry. 1985;48:838-840. Resumo
83. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28:140-175. Resumo
84. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65:62-67.Texto completo Resumo
85. Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591.Texto completo Resumo
86. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1997;49:657-659. Resumo
87. Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:533-536. Resumo
88. Costa J, Rocha ML, Ferreira J, et al. Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol. 2008;255:545-550. Resumo
89. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281. Resumo
90. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512. Resumo
91. Weiss MD, Macklin EA, Simmons Z, et al; Mexiletine ALS Study Group. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86:1474-1481.Texto completo Resumo
92. Beghi E, Pupillo E, Bonito V, et al; Italian ALS Study Group. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:397-405. Resumo
93. DiPALS Writing Committee; DiPALS Study Group Collaborators, McDermott CJ, Bradburn MJ, et al. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14:883-892.Texto completo Resumo
94. Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15:1217-1227. Resumo
95. Abdul Wahid SF, Law ZK, Ismail NA, Lai NM. Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2019 Dec 19;(12): CD011742.Texto completo Resumo
96. ClinicalTrials.gov. The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from amyotrophic lateral sclerosis (ALS): NCT02588677. http://clinicaltrials.govTexto completo
97. ClinicalTrials.gov. Ibudilast (MN-166) in subjects with amyotrophic lateral sclerosis (ALS) (IBU-ALS-1201): NCT02238626. http://clinicaltrials.govTexto completo
98. ClinicalTrials.gov. AMX0035 in Patients with Amyotrophic Lateral Sclerosis (CENTAUR): NCT03127514 [internet publication].Texto completo
99. ClinicalTrials.gov. Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis (TUDCA-ALS): NCT00877604. November 2014 [internet publication].Texto completo
100. ClinicalTrials.gov. Single and multiple dose study of BIIB067 in adults with amyotrophic lateral sclerosis (ALS): NCT02623699. http://clinicaltrials.govTexto completo
101. Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry. 2003;74:995-997. Resumo
102. Chiò A, Logroscino G, Hardiman O, et al; Eurals Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310-323. Resumo
103. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. 1989;12:833-841. Resumo
104. Eisen A, Schulzer M, MacNeil M, et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993;16:27-32. Resumo
105. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390-392. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal